Characterizing the Health-Related Quality of Life Burden of Overactive Bladder Using Disease-Specific Patient-Reported Outcome Measures: A Systematic Literature Review

Abstract

IntroductionThe objective was to identify the most commonly used patient-reported outcome (PRO) instruments for overactive bladder (OAB), determine which are the most useful for measuring burden in OAB and characterize the findings of recent studies that have employed PRO instruments to assess OAB symptoms and the effects of treatment.MethodsA systematic search of OAB literature published between January 2006 and November 2017 using Medline/PubMed and EMBASE databases.ResultsOf 3425 abstracts and 500 full-text articles reviewed, 58 studies (both clinical trials and observational studies) were included in the review. The most commonly used PRO instruments were the OAB Questionnaire (OAB-q; 64%), followed by the King’s Health Questionnaire (KHQ; 31%) and the Patient Perception of Bladder Condition (PCBC; 21%). Synthesis of data from studies using the OAB-q showed that OAB treatment with antimuscarinics, mirabegron and onabotulinumtoxinA all improve health-related quality of life (HRQoL) and symptoms beyond the benefits observed with placebo. The OAB-q could detect dose–response relationships in some studies and demonstrated there were no significant differences across therapies from different drug classes.ConclusionThe HRQoL burden of OAB and response to treatment can be reliably measured by PRO instruments, and the OAB-q is the most commonly used instrument in OAB, particularly in clinical trials of OAB interventions. These data will be useful to provide benchmarks of burden levels for PRO scores obtained among those on contemporary therapies for comparison with outcomes from patients managed with emerging treatments.FundingAstellas Pharma Global Development, Inc.Electronic supplementary materialThe online version of this article (10.1007/s12325-019-0880-8) contains supplementary material, which is available to authorized users.

Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study

“…The role of neurogenic inflammation and pain in endometriosis [ 49 ], high expression of P2X3 receptors in endometrial lesions [ 7 ], and the reversal of hyperalgesia by a P2X3 receptor antagonist in an in vivo endometriosis model [ 50 ] (also observed in unpublished data, Bayer AG, Berlin, Germany) suggest that such agents may be effective. P2X3 receptors are also implicated in the control of urinary bladder volume reflexes in OAB, which affects up to 33% of women and 16% of men [ 4 , 51 , 52 ]. Overactive bladder negatively affects patients’ quality of life, mental health, and daily activities, urinary incontinence being the most common symptom [ 51 ].…”

Peroneal Electric Transcutaneous NeuroModulation (eTNM®): A Novel Method for the Treatment of the Overactive Bladder

“…OAB syndrome is a chronic medical condition with a proven detrimental impact on QoL and well-documented health consequences for affected individuals [ 17 ]. Its treatment goals include maximizing symptom control and QoL while minimizing adverse events [ 18 ].…”

Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR

“…This common and chronic condition can have a profound impact on patient's lives by causing embarrassment, impairing daily functioning and relationships, and in some cases requiring patients to plan their lives around accommodating their symptoms [3][4][5]. Accordingly, OAB has been shown to negatively affect healthrelated quality of life (QoL) and contribute to symptoms of anxiety and depression [6][7][8]. Among patients with OAB, the severity of OAB symptoms is positively correlated with the severity of anxiety and depression symptoms [9,10].…”